USP9X
Overview
USP9X (Ubiquitin Specific Peptidase 9 X-Linked) is a deubiquitinase that regulates the stability of multiple oncoproteins and tumor suppressors. Inactivating mutations in USP9X are observed in ER-positive breast cancer where they associate with significantly worse breast-cancer-specific survival, nominating USP9X as a tumor suppressor in this context. USP9X is also a recognized driver in other cancer types, supporting cross-cancer drug-repurposing hypotheses.
Alterations observed in the corpus
- Inactivating mutations in USP9X associated with worse breast-cancer-specific survival in ER+ tumors (HR=3.0); identified as a Mut-driver candidate in breast cancer via 2,433-sample targeted-panel WES (METABRIC/ICGC) PMID:27161491.
Cancer types (linked)
- BRCA (ER+): Inactivating mutations associated with significantly worse BCSS (HR=3.0); nominated as a Mut-driver and flagged for cross-cancer therapeutic relevance PMID:27161491.
Co-occurrence and mutual exclusivity
- No co-occurrence or mutual exclusivity data with specific partner genes reported in the current corpus.
Therapeutic relevance
- USP9X is a well-known driver in other cancer types (e.g., pancreatic adenocarcinoma); therapies developed in those contexts may be applicable to USP9X-deficient ER+ breast cancers PMID:27161491.
Open questions
- The precise mechanism by which USP9X inactivation promotes worse outcomes in ER+ breast cancer is uncharacterized in the citing study; functional experiments to determine USP9X substrate dependence in breast cancer are needed.
Sources
This page was processed by entity-page-writer on 2026-05-15.